IDiyas

For the Inventor, By the Inventor

Montclair, NJ, United States of America

Noal Cohen

USPTO Granted Patents = 52

Average Co-Inventor Count = 1.7

ph-index = 6

Forward Citations = 120(Granted Patents)

Forward Citations (Not Self Cited) = 111(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Essex, NJ (US) (1993)
  • Montclair, NJ (US) (1976 - 1995)

Company Filing History:

goldMedal52 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents

Years Active: 1976-1995

Loading Chart...
52 patents (USPTO):Explore Patents
1. 5457124 - Carboxylic acid Leukotriene B4 antagonists (1995-10-10),
2. 5434186 - Carboxylic acid leukotriene B.sub.4 antagonists (1995-07-18),
3. 5273999 - Carboxylic acid leukotriene B4 antagonists (1993-12-28),
4. 4942249 - Process for producing vitamin E (1990-07-17),
5. 4877890 - Vitamin E intermediate (1989-10-31),
6. 4824971 - 2-allylchromans (1989-04-25),
7. 4806661 - Chromanemelonate esters (1989-02-21),
8. 4801724 - Vitamin E intermediate (1989-01-31),
9. 4788214 - 3,4-dihydro-2H-1-benzopyran derivatives (1988-11-29),
10. 4785017 - 3,4-dihydro-2H-1-benzopyran derivatives (1988-11-15),
11. 4752646 - 2-halochromans (1988-06-21),
12. 4650812 - 4-oxo-3,4-dihydro-2H-1-benzopyranyloxy alkanoic acid derivatives (1987-03-17),
13. 4434101 - Inhibitors of SRS-synthesis (1984-02-28),
14. 4432906 - Inhibitors of SRS-synthesis (1984-02-21),
15. 4277610 - Synthesis of 2,6,10-trimethyl-undecan-1-ol (1981-07-07),

Title: The Innovative Contributions of Noal Cohen in Drug Development

Introduction: Noal Cohen, a prolific inventor based in Montclair, NJ, has made significant strides in the field of pharmaceuticals with an impressive portfolio of 52 patents. His work primarily focuses on leukotriene B4 antagonists, which are crucial in addressing various inflammatory diseases.

Latest Patents: Among his latest innovations, Cohen has developed carboxylic acid leukotriene B4 antagonists. These compounds, identified by specific formulas, demonstrate potent activity, aiding in the treatment of inflammatory conditions. The formulations he has worked on include compounds where specific groups such as R² and Ph play vital roles in their effectiveness.

Career Highlights: Cohen is currently associated with Hoffmann-La Roche Inc., a leading organization in the pharmaceutical industry. His extensive research and development work have positioned him as a key figure in the innovative landscape of drug formulation, particularly focusing on the antagonistic properties of leukotrienes.

Collaborations: Throughout his career, Noal Cohen has collaborated with notable colleagues such as Gabriel G. Saucy and Michael Rosenberger. These partnerships have facilitated the exchange of ideas and propelled forward his contributions to the field of therapeutics.

Conclusion: Noal Cohen's ongoing dedication to innovation within pharmaceutical sciences is evident through his numerous patents and collaborative efforts. His research not only underscores the importance of drug development but also highlights his role in paving the way for new treatments aimed at managing inflammatory diseases effectively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…